Amit Munshi
CIK 1612551 · President and CEO · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ARNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
699 BOYLSTON STREET, 8TH FLOOR
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZURA | Director | 777,384 | $3.71 | $2.89M | $0 | 4 | 2026-06-22 |
| ARQT | Director | 9,799 | $31.78 | $311.4K | $0 | 2 | 2026-06-09 |
| IKT | Director | 403,176 | $1.54 | $620.9K | $500.1K | 5 | 2026-02-24 |
| Damora Therapeutics, Inc. (GLTO) Delisted | Director | 192 | $28.69 | $5.5K | $0 | 5 | 2025-06-20 |
| Zura Bio Ltd (ZURAW) Delisted | Director | 777,384 | $1.08 | $839.6K | $1000.0K | 3 | 2024-04-24 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | President and CEO | 114,647 | $99.99 | $11.46M | -$28.99M | 24 | 2022-03-11 |
| PULM | Director | — | $1.51 | — | $0 | 6 | 2021-02-01 |
| EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Chief Executive Officer | 301,841 | — | — | $221.8K | 10 | 2016-03-01 |
Recent Filings · Page 6 of 6
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-12-17 | EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Buy (P) | +8,270 | $23.2K | EDGAR |
| 2015-12-16 | EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Buy (P) | +8,069 | $23.2K | EDGAR |
| 2015-12-10 | EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Buy (P) | +13,190 | $53.7K | EDGAR |
| 2015-11-03 | EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-09-22 | EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Buy (P) | +10,000 | $61.9K | EDGAR |
| 2015-09-21 | EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Buy (P) | +10,000 | $59.9K | EDGAR |
| 2015-07-06 | EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Exer (M) | +51,200 | $51.2K | EDGAR |
| 2015-03-02 | EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-07-17 | EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Grant (A) | +69,253 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.